Monitoring of exhaled nitric oxide (FENO) to tailor the lowest effective dose of oral corticosteroids in severe asthma (MONOSA-Study).
Completed
- Conditions
- 1. Severe asthma<br /> 2. corticosteroids<br />3. adverse effects<br />4. nitric oxide.<br /> (NLD: Ernstig astma, corticosteroid, bijwerkingen, stikstofoxide).
- Registration Number
- NL-OMON19976
- Lead Sponsor
- Academic Medical Center, Amsterdam University;Medical Center Leeuwarden ;Haga Ziekenhuis den Haag;Medisch Spectrum Twente;Leiden University Medical Center
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
1. 18-65 years;
2. Pulmonologysts’ diagnosis of severe asthma;
Exclusion Criteria
1. Patient not able to perform adequate measurements of FENO at home;
2. Patient without mobile phone or internet access.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Cumulative dose of OCS;<br /><br>2. symptoms (ACQ);<br /><br>3. quality of life (AQLQ);<br /><br>4. patient's health state (VAS).
- Secondary Outcome Measures
Name Time Method 1. EQ-5D;<br /><br>2. SF-12;<br /><br>3. lung function;<br /><br>4. exacerbations;<br /> <br>5. emergency visits;<br /><br>6. hospitalisations;<br /> <br>7. steroid side effects.<br>